Breaking News: Corvia Medical Secures $55M Funding for Groundbreaking Heart Failure Trial
Corvia Medical, Inc., a pioneer in heart failure treatment solutions, announced on June 17, 2025, the successful closure of a $55 million financing round with its existing investor union.
Transformative Treatment for Millions
Corvia Medical’s recent funding will be used to complete the international REDUCE-HF study, a crucial double-blind, randomized clinical trial held at more than 65 institutions across three continents. The study aims to gather the final clinical data necessary for the FDA approval of the Corvia® Atrial Shunt as an innovative treatment for heart failure with preserved and slightly reduced ejection fraction (HFpEF/HFrEF).
Investor Support and Vision
Leading investors including Third Rock Ventures, General Catalyst Partners, Accelmed, Lumira Ventures, and two strategic investors have shown unwavering support for Corvia Medical. George Fazio, CEO of Corvia Medical, expressed gratitude for the investors’ commitment, emphasizing that their support is instrumental in advancing this crucial treatment toward FDA submission.
Potential to Revolutionize Heart Failure Treatment
Heart failure, which affects over 26 million people worldwide, remains one of the biggest unmet clinical needs in cardiovascular medicine. The Corvia Atrial Shunt is designed to address high left atrial pressure, the primary cause of heart failure symptoms, by creating a passage between the left and right atria, thereby improving patients’ quality of life. The FDA granted the Corvia Atrial Shunt Breakthrough Device designation in 2019.
Funding the Future of Cardiology
Founded in 2009, Corvia Medical is committed to transforming the standard of care for heart failure. With this infusion of funds, the company is well-positioned to navigate the approval process and introduce its revolutionary therapy to patients worldwide. Paul Laviolette, Chairman of Corvia Medical, believes this innovative technology has the potential to significantly alter the landscape of heart failure treatment.
The Road Ahead
As part of the REDUCE-HF study, current and potential participants can learn more about eligibility and the ongoing trial at [https://treatmyheartfailure.com](https://treatmyheartfailure.com). This study is a critical step towards enhancing the lives of millions of individuals suffering from heart failure. Keeping up with the latest breakthroughs in heart failure treatment can be achieved by staying tuned to archyde.com for further developments.
For More Information
For media inquiries, contact Lisa at [protected].
